908 Devices is expected to report a Q3 2026 loss of $0.16 per share on revenue of $18.31 million, with the stock currently trading at $10.56 against a $13.38 analyst price target.

Investors are primarily focused on the growth momentum of handheld devices like the MX908, particularly as management seeks to capitalize on increased demand for point-of-need chemical analysis in safety and defense.

This quarter is critical for proving that the company can sustain its 30.7% year-over-year revenue growth trajectory to achieve its recently raised full-year guidance of $68 million to $70 million. Analysts are also monitoring the balance between hardware shipments and the growth of high-margin recurring revenue from consumables and services.